These delays will cost thousands of lives. Incremental change will fail.
For a decade, the National Health Service in England has quietly normalized a crisis: more than half a million cancer patients have waited longer than two months to begin treatment, while the system has missed its own targets every single month since 2015. The arithmetic is unsparing — each four-week delay raises the risk of death by up to 10 percent, meaning that institutional inertia has translated, for thousands of people, into shortened lives. As the government prepares to unveil a new cancer plan on World Cancer Day, the deeper question is whether a system that has learned to accept failure can summon the will to genuinely change.
- 506,335 cancer patients waited over 62 days for treatment across a decade — a number so large it has ceased to shock, which is itself part of the danger.
- The NHS has missed its 85% on-time treatment target every single month since December 2015, and today only 69% of patients begin cancer care within the window.
- The delays fall hardest on the most vulnerable: nearly half of gynaecological and lower GI cancer patients miss the target, and lung cancer patients — whose disease punishes every lost week — are among the worst served.
- A new government cancer plan launches Tuesday, but the health secretary has already declined to commit to meeting national targets before the end of parliament, and an earlier early-diagnosis target has been quietly scrapped.
- Leading oncologists warn that incremental reform will not be enough — thousands more deaths are projected unless the plan confronts the structural bottlenecks with genuine urgency and ambition.
Over the past decade, more than half a million cancer patients in England have waited longer than two months for treatment to begin. Analysis of NHS figures by Radiotherapy UK puts the number at 506,335 — and what makes it especially troubling is that the delay has become routine. The NHS has failed to meet its own 85 percent on-time target every single month since December 2015, and today only 69 percent of patients start treatment within the 62-day window.
The human cost is not abstract. International research shows that for every four weeks a cancer patient waits, their risk of death rises by up to 10 percent. Experts warn that thousands will die prematurely unless the NHS dismantles the bottlenecks that have hardened over the past decade. The delays are also deeply unequal: nearly half of all patients with gynaecological and lower gastrointestinal cancers miss the target window, lung and urological cancer patients fare similarly, and even breast cancer — among the better-performing types — still sees 28 percent of patients waiting beyond two months. Skin cancer stands as the lone exception, with over 80 percent treated on time.
The government is set to launch a new cancer plan on Tuesday, timed to World Cancer Day, but skepticism runs deep. Health secretary Wes Streeting has signaled the government will not commit to meeting national targets by the end of this parliament, and an earlier goal to diagnose 75 percent of cancers at stage 1 or 2 has already been scrapped.
Leading voices across the cancer community are united in their alarm. Pat Price of Radiotherapy UK warned that incremental change will fail and that only a bold plan can prevent thousands of needless deaths. Professor Mark Lawler, Paula Chadwick of the Roy Castle Lung Cancer Foundation, Cancer Research UK, and Breast Cancer Now all called for urgent, systemic action across the full pathway of diagnosis, treatment, and survival. The Department of Health pointed to reforms expected to bring 120,000 more patients into timely diagnosis and treatment — but for those who have already waited, the question is whether this plan will finally break a pattern a decade in the making.
Over the past decade, more than half a million cancer patients in England have waited longer than two months for treatment to begin. The number is staggering in its scale: 506,335 people, according to analysis of NHS figures by Radiotherapy UK. What makes it worse is that this delay has become the norm. The health service has failed to meet its own target of getting 85 percent of patients into treatment within 62 days every single month since December 2015. Today, only 69 percent of patients start their cancer treatment on time.
The human cost of these delays is not abstract. International research is clear: for every four weeks a cancer patient waits, their risk of death increases by up to 10 percent. Experts are now warning that thousands of people will die prematurely unless the NHS moves with genuine urgency to dismantle the bottlenecks that have calcified over the past decade. The problem is not new, but the scale of it—and the acceptance of it—has become normalized in ways that alarm those who study cancer outcomes.
The delays are not distributed equally. Analysis exclusive to The Guardian reveals stark disparities in how long different cancer types take to reach treatment. Nearly half of all patients with gynaecological cancers and lower gastrointestinal cancers never make the 62-day window. Lung cancer patients fare similarly poorly: 42.3 percent miss the target. Urological cancer patients are at 42.5 percent. Even breast cancer, which performs better than most, still sees 28.4 percent of patients waiting beyond two months. The one exception is skin cancer, where more than 80 percent of patients have begun treatment within the target since February 2024—a reflection, experts note, of the relative straightforwardness of treating that particular malignancy.
The government is set to unveil a new cancer plan on Tuesday, timed to coincide with World Cancer Day. But there is deep skepticism about whether it will contain the structural changes the system desperately needs. The health secretary, Wes Streeting, has already signaled that the government will not commit to meeting national cancer targets by the end of this parliament. The NHS also scrapped an earlier target to diagnose 75 percent of cancers at stage 1 or 2—a decision that, combined with the treatment delays, means patients are being diagnosed later and waiting longer for care.
Pat Price, chair of Radiotherapy UK and a leading oncologist, put it bluntly: the past decade of cancer leadership has normalized dangerous delays and unacceptably low ambitions. "These delays will cost thousands of lives," she said. "We need a brave and bold cancer plan or even more lives will be lost needlessly in the next decade. Incremental change will fail." Mark Lawler, a professor of digital health at Queen's University Belfast and chair of the International Cancer Benchmarking Partnership, echoed the concern: "Thousands more patients will die unnecessarily unless the cancer plan gets to grips with treatment delays urgently."
Paula Chadwick, chief executive of the Roy Castle Lung Cancer Foundation, emphasized the particular danger for lung cancer patients, whose disease is aggressive and demands swift intervention. Michelle Mitchell, Cancer Research UK's chief executive, called for the government to renew its ambitions across the entire pathway—diagnosis, treatment, and survival. Melanie Sturtevant of Breast Cancer Now described the delays as leaving patients with "agonising waits for the care they should be able to count on."
The Department of Health and Social Care responded with a statement emphasizing its commitment to transforming cancer care and noting that reforms are expected to see around 120,000 more people referred for urgent cancer checks receive a diagnosis within four weeks and start treatment within two months. The NHS, for its part, acknowledged that while more people are being diagnosed at early stages and survival rates have improved, much more work remains to ensure timely diagnosis and treatment across the board.
What hangs over all of this is a simple, terrible arithmetic: half a million people have already waited too long. The question now is whether the government's new plan will finally break the pattern that has held since 2015, or whether it will simply add more names to the list of those whose cancer progressed while they waited.
Notable Quotes
The last decade of leadership in cancer has normalised dangerous delays and unacceptably low ambitions. These delays will cost thousands of lives.— Pat Price, chair of Radiotherapy UK
Thousands more patients will die unnecessarily unless the cancer plan gets to grips with treatment delays urgently.— Mark Lawler, International Cancer Benchmarking Partnership
The Hearth Conversation Another angle on the story
Why does it matter that these delays have persisted since 2015? Couldn't the NHS have fixed this years ago?
Yes, and that's precisely what makes it so damning. This isn't a new problem that suddenly emerged. It's a target the system has missed for nearly a decade. That suggests either the target was set without the resources to meet it, or the resources were never allocated. Either way, it's a failure of planning and will.
The disparities between cancer types are striking. Why does skin cancer do so much better than lung cancer?
Skin cancer is often simpler to treat—less complex surgery, fewer complications. But that's not really the point. The point is that if the system can do it for skin cancer, it proves the capacity exists. The question becomes: why isn't that capacity being directed toward lung cancer or gynaecological cancers, where the stakes are just as high?
The government says it will get 120,000 more people diagnosed within four weeks. That sounds like progress.
It does, until you remember that diagnosis without timely treatment is just a cruel half-measure. You're telling someone they have cancer, then making them wait. One expert put it perfectly: you're just adding more patients to growing waiting lists while their cancer progresses.
What does it mean that the health secretary won't commit to meeting targets by the end of parliament?
It means the government is already setting itself up for failure. It's saying, in advance, that it doesn't expect to solve this. That's not a plan—that's a surrender dressed up as realism.
Is there any reason to think the new cancer plan will be different?
The experts don't seem to think so. They're calling for "brave and bold" change, which is code for: we've seen incremental plans before, and they haven't worked. The system needs to be fundamentally restructured, not tinkered with.